Atlas Trials

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Clinical trial NCT05445154 · RECRUITING

Trial details

NCT number
NCT05445154
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Newly Diagnosed Acute Myeloid Leukemia (AML)
Start date
2021-08-31
Primary completion
2024-10-31
Enrollment
58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.